Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 5/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399157 | 1.00 | TDP1 (0.53) | TDP1POLBRAB9AGPR183F2R | |
| SCHEMBL1399112 | 0.87 | F2R (0.46) | TDP1POLBGPR183F2RMEN1 | |
| SCHEMBL1399110 | 0.87 | F2R (0.46) | TDP1POLBGPR183F2RMEN1 | |
| SCHEMBL1399050 | 0.81 | GPR183 (0.60) | TDP1GPR183F2R | |
| SCHEMBL1399048 | 0.81 | GPR183 (0.60) | TDP1GPR183F2R | |
| SCHEMBL1399078 | 0.79 | MAPT (0.56) | TDP1POLBGPR183F2RMEN1 | |
| SCHEMBL1399075 | 0.79 | MAPT (0.56) | TDP1POLBGPR183F2RMEN1 | |
| SCHEMBL3934180 | 0.78 | TDP1 (0.38) | TDP1POLBRAB9AKMT2AGAA | |
| SCHEMBL1399054 | 0.76 | LMNA (0.53) | TDP1POLBRAB9AMEN1KMT2A | |
| SCHEMBL1399052 | 0.76 | LMNA (0.53) | TDP1POLBRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022064-B2 | Phenylpentadienoyl derivatives and their use as PAR 1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2011-09-20 | — | — | US | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | claimed |
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-07 | — | — | US | claimed |
| EP-2046748-B1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | PF MEDICAMENT (FR) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003260-A1 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS | F2R, F2RL1, FPR1 | TDP1 524/4885POLB 3354/4885RAB9A 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.